#1 Clinical Trials Search in Europe

Mirodenafil Dihydrochloride

This article discusses the ongoing clinical trials investigating the use of Mirodenafil Dihydrochloride, also known as AR1001, in treating early Alzheimer’s Disease. The drug is being studied in a Phase 3 trial to evaluate its efficacy and safety over a 52-week period. This research aims to provide new insights into potential treatments for individuals experiencing mild cognitive impairment or mild dementia associated with Alzheimer’s Disease.

Table of Contents

What is Mirodenafil Dihydrochloride?

Mirodenafil Dihydrochloride, also known as AR1001, is a medication currently being studied for its potential in treating early Alzheimer’s disease[1]. It belongs to a class of drugs called PDE5 inhibitors, which are typically used to treat conditions like erectile dysfunction. However, researchers are now exploring its possible benefits for brain health and cognitive function.

Mirodenafil as a Potential Alzheimer’s Treatment

Alzheimer’s disease is a progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks[1]. Currently, there is no cure for Alzheimer’s, but researchers are constantly looking for new treatments to slow its progression or improve symptoms. Mirodenafil Dihydrochloride is being investigated as a potential new option for people with early-stage Alzheimer’s disease.

Current Clinical Trial

A large-scale clinical trial, known as AR1001-ADP3-US01, is currently underway to evaluate the effectiveness and safety of Mirodenafil Dihydrochloride in people with early Alzheimer’s disease[1]. This is a Phase 3 trial, which means it’s in an advanced stage of testing before the drug can potentially be approved for widespread use.

Key features of the trial include:

  • It’s a double-blind, randomized, placebo-controlled study
  • The trial will last for 52 weeks (about one year)
  • It’s being conducted at multiple medical centers

Who Can Participate in the Study?

The study is looking for participants who meet specific criteria[1]. Some key eligibility factors include:

  • Age: 55 to 85 years old
  • Diagnosis: Mild cognitive impairment or mild dementia due to Alzheimer’s disease
  • Cognitive status:
    • MMSE score (a test of cognitive function) of 20 or higher
    • CDR global rating (a measure of dementia severity) of 0.5 or 1
  • Evidence of brain amyloid pathology (a hallmark of Alzheimer’s disease)
  • Having a study partner who can report on the participant’s condition

There are also several exclusion criteria, such as certain medical conditions or use of specific medications, that would prevent someone from participating in the study.

Study Objectives and Measurements

The main goal of the study is to see if Mirodenafil Dihydrochloride can slow down the progression of Alzheimer’s disease. Researchers will measure this using several tests and scales[1]:

  • CDR-SB (Clinical Dementia Rating Scale-Sum of Boxes): This is the primary measure, looking at changes in cognitive and functional abilities
  • ADAS-Cog 13 (Alzheimer’s Disease Assessment Scale – Cognitive Subscale): This test assesses cognitive function
  • A-IADL-Q-SV (Amsterdam-Instrumental Activities of Daily Living Questionnaire): This measures ability to perform daily activities
  • GDS-15 (Geriatric Depression Scale): This assesses mood and depression symptoms
  • MMSE (Mini-Mental Status Examination): This is another test of cognitive function

Dosage and Administration

In this study, Mirodenafil Dihydrochloride is being given as a film-coated tablet to be taken orally[1]. The maximum daily dose being tested is 30 mg. The study will last for about 107 weeks, with a total maximum dose of 22,530 mg over the entire study period.

Important Considerations

While this research is promising, it’s important to remember that Mirodenafil Dihydrochloride is still an experimental treatment for Alzheimer’s disease[1]. It has not yet been approved for this use, and more research is needed to determine its effectiveness and safety. If you or a loved one has Alzheimer’s disease, always consult with a healthcare provider about the best treatment options.

Aspect Details
Drug Name Mirodenafil Dihydrochloride (AR1001)
Trial Phase Phase 3
Trial Design Double-blind, Randomized, Placebo-controlled, Multi-center
Target Condition Early Alzheimer’s Disease
Trial Duration 52 weeks
Age Range 55 to 85 years
Primary Endpoint Change in CDR-SB from Baseline to Week 52
Key Secondary Endpoints Changes in ADAS-Cog 13, A-IADL-Q-SV, GDS-15, and MMSE
Dosage Form Film Coated Tablet
Administration Route Oral

FAQ

  • What is Mirodenafil Dihydrochloride? Mirodenafil Dihydrochloride, also known as AR1001, is a drug being studied for its potential in treating early Alzheimer's Disease. It is currently undergoing clinical trials to evaluate its effectiveness and safety.
  • Who can participate in this clinical trial? The trial is open to men and women aged 55 to 85 years with mild cognitive impairment or mild dementia consistent with early Alzheimer's Disease. Participants must meet specific criteria, including having a history of cognitive decline and positive biomarkers for brain amyloid pathology.
  • How long does the clinical trial last? The clinical trial lasts for 52 weeks (about one year). During this time, researchers will evaluate the efficacy and safety of AR1001 compared to a placebo in participants with early Alzheimer's Disease.
  • What are the main goals of this clinical trial? The primary goal is to evaluate the efficacy of AR1001 compared to a placebo in participants with early Alzheimer's Disease. Researchers will measure changes in cognitive function, daily living activities, and depression symptoms over the course of the trial.
  • Are there any specific exclusion criteria for the trial? Yes, there are several exclusion criteria. These include having other forms of dementia, significant psychiatric disorders, uncontrolled hypertension, recent history of heart problems, and use of certain medications. Pregnant women and those with a body mass index over 35 kg/m² are also excluded.

Ongoing Clinical Trials on Mirodenafil Dihydrochloride

  • Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer’s Disease

    Not recruiting

    3 1
    Investigated drugs:
    Czechia Denmark France Germany Italy The Netherlands +2

Glossary

  • Alzheimer's Disease: A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, including memory and thinking skills.
  • Amyloid: A protein that can build up in the brain, forming plaques that are associated with Alzheimer's Disease.
  • Biomarker: A measurable indicator that can be used to determine the presence or progress of a disease or condition.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a drug against no treatment.
  • Efficacy: The ability of a drug or treatment to produce the desired effect.
  • Phase 3 Trial: A large-scale clinical study that tests the safety and effectiveness of a new drug in a larger population of patients.
  • CDR-SB: Clinical Dementia Rating Scale-Sum of Boxes, a tool used to measure cognitive and functional performance in Alzheimer's Disease.
  • ADAS-Cog 13: Alzheimer's Disease Assessment Scale – Cognitive Subscale 13, a test used to measure cognitive function in Alzheimer's patients.
  • MMSE: Mini-Mental Status Examination, a widely used test of cognitive function.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-ar1001-mirodenafil-dihydrochloride-for-patients-with-early-alzheimers-disease/